awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q35231826-CF031900-0457-4F2B-9683-E56EB976E6D7
Q35231826-CF031900-0457-4F2B-9683-E56EB976E6D7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35231826-CF031900-0457-4F2B-9683-E56EB976E6D7
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
P2860
Q35231826-CF031900-0457-4F2B-9683-E56EB976E6D7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35231826-CF031900-0457-4F2B-9683-E56EB976E6D7
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1c65682014fa28f5cc913d4b0615466302ba0db3
P2860
Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.